(1222-C) At-scale Enablement of a Human Bronchial Epithelial (huBEC) Cell Air Liquid Interface (ALI) Model for Respiratory Antiviral Program Support with Potential for Improved Human Physiological Relevance
Tuesday, February 6, 2024
12:00 PM – 1:00 PM EST
Location: Exhibit Halls AB
Abstract: Recent progress in the propagation and differentiation of primary human bronchial epithelial cells (huBECs) at an air liquid interface (ALI) offers an exciting opportunity for respiratory virus research by providing a model with improved translatability to human biology. However, complex in vitro models are challenging to create and utilize at a scale and consistency that can be relied upon for routine screening support. Here we present details outlining the production of a 96 well format huBEC ALI culture to enable at-scale pharmacological interrogation of viral infection for drug discovery. First, we demonstrate successful automation of 96 well huBEC culture maintenance using standard liquid handling and robotic equipment. Next, we demonstrate automated infection of huBEC ALI cultures by respiratory syncytial virus (RSV) engineered with green fluorescent protein (GFP), allowing for the use of high-content imaging techniques to capture longitudinal viral growth kinetics. Finally, we demonstrate reproducible antiviral dose response curves for reference compounds as a part of routine program support, allowing for more physiologically relevant evaluation of investigational compounds for respiratory virus drug discovery.